Novartis to invest $610m in new S'pore biotech site

ZURICH - Swiss drugmaker Novartis said on Wednesday it would spend more than US$500 million (S$610 million) on a new biotechnology production site in Singapore to support its growing pipeline of biologics.

The Basel-based company said construction of the new site would begin in early 2013 and the facility is expected to be fully operational by the end of 2016.

Novartis said the site will focus on drug substance manufacturing based on cell culture technology.

Purchase this article for republication.
Your daily good stuff - AsiaOne stories delivered straight to your inbox
By signing up, you agree to our Privacy policy and Terms and Conditions.